Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Olinciguat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUCY1B2 known ✓ | O75343 | 20/20 | 0.69 |
| ▸ | GUCY1A2 known ✓ | P33402 | 20/20 | 0.69 |
| ▸ | GUCY1A1 known ✓ | Q02108 | 20/20 | 0.69 |
| ▸ | GUCY1B1 known ✓ | Q02153 | 20/20 | 0.69 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Olinciguat SCHEMBL16081941 | 1.00 | GUCY1B2 (0.69) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| Olinciguat SCHEMBL16082282 | 1.00 | GUCY1B2 (0.69) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| Olinciguat SCHEMBL16081945 | 1.00 | GUCY1B2 (0.69) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL16082087 | 0.94 | GUCY1B2 (0.60) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL17611686 | 0.93 | GUCY1B2 (0.68) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL16081910 | 0.93 | GUCY1B2 (0.70) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL26866727 | 0.92 | GUCY1B2 (0.67) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL25966687 | 0.92 | GUCY1B2 (0.71) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL18854998 | 0.92 | GUCY1B2 (0.71) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL16082433 | 0.92 | GUCY1B2 (0.71) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3952992-A1 | METHODS AND MATERIALS FOR GENDER-DEPENDENT TREATMENT OF CARDIOVASCULAR DYSFUNCTION | Mayo Foundation for Medical Education and Research (US) | 2022-02-16 | — | — | EP | claimed |
| US-20250129060-A1 | SOLID FORMS OF AN SGC STIMULATOR | CYCLERION THERAPEUTICS INC (US) | 2025-04-24 | — | — | US | disclosed |
| EP-4313992-A1 | POLYMORPHIC FORMS OF (S)-12-FLUORO-4-(1-METHYL-1H-PYRAZOL-5-YL)-7A,8,13,14-TETRAHYDRO-7H-[1,2,4]TRIAZOLO[4',3':1,6]PYRIDO[3,2-B]BENZOFURO[4,3-FG][1,4]OXAZONINE | Fulcrum Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| EP-4313993-A1 | MACROCYCLIC AZOLOPYRIDINES | Fulcrum Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| EP-3481821-B1 | NOVEL PROCESSES FOR PREPARATION OF SOLUBLE GUANYLATE CYCLASE STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2023-09-06 | — | — | EP | disclosed |
| WO-2022212748-A1 | POLYMORPHIC FORMS OF (S)-12-FLUORO-4-(1-METHYL-1H-PYRAZOL-5-YL)-7A,8,13,14-TETRAHYDRO-7H-[1,2,4]TRIAZOLO[4',3':1,6]PYRIDO[3,2-B]BENZOFURO[4,3-FG][1,4]OXAZONINE | Fulcrum Therapeutics, Inc. (US) | 2022-10-06 | — | — | WO | disclosed |
| WO-2022212746-A1 | MACROCYCLIC AZOLOPYRIDINES | Fulcrum Therapeutics, Inc. (US) | 2022-10-06 | — | — | WO | disclosed |
| EP-3952992-A1 | METHODS AND MATERIALS FOR GENDER-DEPENDENT TREATMENT OF CARDIOVASCULAR DYSFUNCTION | Mayo Foundation for Medical Education and Research (US) | 2022-02-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129060-A1 | SOLID FORMS OF AN SGC STIMULATOR | GUCY1A2, PRKG1, GUCY1A1 | GUCY1B2 7/4885GUCY1A2 1/4885GUCY1A1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.